Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients

Biomarker Research

Anders Sundan²  Anders Waage¹  Magne Børset²  Tobias Schmidt Slørdahl²  Glenn Buene²  Thea Kristin Våtsveen²  Erming Tian³  Christoph Rampa² 

[1]Section of Hematology, St. Olavs University Hospital, Trondheim, Norway

[2]The K. G. Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

[3]The Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

关键词: Co-cultivation;    DNA sequencing;    Fluorescence in situ hybridization;    Microarray;    Bone marrow core biopsies;    Scatter factor;    Hepatocyte growth factor;    Multiple myeloma;   

Others  :  791717
DOI  :  10.1186/2050-7771-2-8

 received in 2014-01-16, accepted in 2014-03-29,  发布年份 2014

【 摘 要 】

Background

Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. HGF levels are elevated in 50% of patients and associated with poor prognosis. Here we aim to investigate its source in myeloma.

Methods

HGF mRNA levels in bone marrow core biopsies from healthy individuals and myeloma patients were quantified by real-time PCR. HGF gene expression profiling in CD138⁺ cells isolated from bone marrow aspirates of healthy individuals and MM patients was performed by microarray analysis. HGF protein concentrations present in peripheral blood of MM patients were measured by enzyme-linked immunosorbent assay (ELISA). Cytogenetic status of CD138⁺ cells was determined by fluorescence in situ hybridization (FISH) and DNA sequencing of the HGF gene promoter. HGF secretion in co-cultures of human myeloma cell lines and bone marrow stromal cells was measured by ELISA.

Results

HGF gene expression profiling in both bone marrow core biopsies and CD138⁺ cells showed elevated HGF mRNA levels in myeloma patients. HGF mRNA levels in biopsies and in myeloma cells correlated. Quantification of HGF protein levels in serum also correlated with HGF mRNA levels in CD138⁺ cells from corresponding patients. Cytogenetic analysis showed myeloma cell clones with HGF copy numbers between 1 and 3 copies. There was no correlation between HGF copy number and HGF mRNA levels. Co-cultivation of the human myeloma cell lines ANBL-6 and JJN3 with bone marrow stromal cells or the HS-5 cell line resulted in a significant increase in secreted HGF.

Conclusions

We here show that in myeloma patients HGF is primarily produced by malignant plasma cells, and that HGF production by these cells might be supported by the bone marrow microenvironment. Considering the fact that elevated HGF serum and plasma levels predict poor prognosis, these findings are of particular importance for patients harbouring a myeloma clone which produces large amounts of HGF.

【 授权许可】

   
2014 Rampa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet 2009, 374:324-339.
• [2]Yasui H, Hideshima T, Richardson PG, Anderson KC: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006, 132:385-397.
• [3]Abe M: Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 2011.
• [4]Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST: Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99:1405-1410.
• [5]Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST: The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
• [6]Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998, 91:806-812.
• [7]Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E: Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002, 116:796-802.
• [8]Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N: Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 2005, 128:210-217.
• [9]Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A: High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000, 96:3139-3146.
• [10]Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Borset M, Waage A: Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002, 119:672-676.
• [11]Mahtouk K, Tjin EP, Spaargaren M, Pals ST: The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 2010.
• [12]Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B: Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010, 10:198.
• [13]Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A: Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996, 271:24655-24661.
• [14]Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996, 88:3998-4004.
• [15]Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M: A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004, 10:6686-6694.
• [16]Wader KF, Fagerli UM, Borset M, Lydersen S, Hov H, Sundan A, Bofin A, Waage A: Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology 2012, 60:443-451.
• [17]Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, International Myeloma Working Group: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
• [18]Borset M, Helseth E, Naume B, Waage A: Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 1993, 85:446-451.
• [19]Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B: A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
• [20]Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.
• [21]Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr: The molecular classification of multiple myeloma. Blood 2006, 108:2020-2028.
• [22]Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr: Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003, 101:1128-1140.
• [23]Ma J, Defrances MC, Zou C, Johnson C, Ferrell R, Zarnegar R: Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009.
• [24]Vatsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Borset M: OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus. Leuk Res 2009, 33:1670-1677.
• [25]Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M: Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 2008, 111:806-815.
• [26]Misund K, Baranowska KA, Holien T, Rampa C, Klein DC, Borset M, Waage A, Sundan A: A Method for Measurement of Drug Sensitivity of Myeloma Cells Co-cultured with Bone Marrow Stromal Cells. In J Biomol Screen 2013.
• [27]Roecklein BA, Torok-Storb B: Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995, 85:997-1005.
• [28]Nilsson K, Bennich H, Johansson SG, Pontén J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970, 7:477-489.
• [29]Weiss A, Wiskocil RL, Stobo JD: The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 1984, 133:123-128.
• [30]Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA: Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993, 53:5320-5327.
• [31]Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M: Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998, 91:1858-1863.
• [32]Jackson N, Lowe J, Ball J, Bromidge E, Ling NR, Larkins S, Griffith MJ, Franklin IM: Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin Exp Immunol 1989, 75:93-99.
• [33]Hjertner O, Hjorth-Hansen H, Börset M, Seidel C, Waage A, Sundan A: Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 2001, 97:516-522.
• [34]Borset M, Waage A, Brekke OL, Helseth E: TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994, 53:31-37.
• [35]HGF (hepatocyte growth factor (hepapoietin A; scatter factor)) [Homo sapiens (human) http://AtlasGeneticsOncology.org/Genes/HGFID385ch7q21.html webcite
• [36]Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol 2013, 6:92. BioMed Central Full Text
• [37]Hoshino K, Satoh T, Kawaguchi Y, Kuwana M: Association of hepatocyte growth factor promoter polymorphism with severity of interstitial lung disease in Japanese patients with systemic sclerosis. Arthritis Rheum 2011, 63:2465-2472.
• [38]Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M: Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011, 29:4789-4795.